Cluster randomized trials in comparative effectiveness research: Randomizing hospitals to test methods for prevention of healthcare-associated infections

Medical Care

Volumn 48, Issue 6 SUPPL., 2010, Pages

  Piatt, Richard ^a   Takvorian, Samuel U ^a   Septimus, Edward ^b   Hickok, Jason ^b   Moody, Julia ^b   Perlin, Jonathan ^b   Jernigan, John A ^c   Kleinman, Ken ^a   Huang, Susan S ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL CORPORATION OF AMERICA   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cluster randomization; Comparative effectiveness; MRSA prevention

Indexed keywords

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SURVEILLANCE; HEALTH CARE PLANNING; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; INFORMATION PROCESSING; INTENSIVE CARE UNIT; MEDICAL PRACTICE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOTAL QUALITY MANAGEMENT; URINARY TRACT INFECTION; CROSS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT;

COMPARATIVE EFFECTIVENESS RESEARCH; CROSS INFECTION; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953649158     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181dbebcf     Document Type: Article

References (44)

1. Institute of Medicine. The Learning Healthcare System: Workshop Summary. Washington, DC: The National Academies Press; 2007.
2. Tunis SR. Strategies to improve comparative effectiveness research methods and data infrastructure. In: Implementing Comparative Effectiveness Research: Priorities, Methods, and Impact. http://www.brookings.edu/~/media/ Files/events/2009/0609-health-care-cer/0609-health-care-cer.pdf. Washington, DC: Brookings; 2009:42-49. Accessed April 1, 2010.
3. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press; 2009.
4. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206-209.
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288: 2981-2997.
6. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:702-708.
7. Murray DM, Varnell SP, Blitstein JL. Design and analysis of grouprandomized trials: a review of recent methodological developments. Am J Public Health. 2004;94:423-432.
8. Jick H, Jick SS, Walker AM, et al. A comparison of wax matrix and microencapsulated potassium chloride in relation to upper gastrointestinal illness requiring hospitalization. Pharmacotherapy. 1989;9:204-206.
9. Schneeweiss S, Maclure M, Carleton B, et al. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004;328:560.
10. Smith DH, Kramer JM, Perrin N, et al. A randomized trial of direct-to- patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008;168:477-483; discussion 483; quiz 447.
11. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis. 2005;41:159-166.
12. Jarvis WR, Schlosser J, Chinn RY, et al. National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. Am J Infect Control. 2007;35:631-637.
13. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med. 2008;148:409-418.
14. Huang SS, Rifas-Shiman SL, Warren DK, et al. Improving methicillinresistant Staphylococcus aureus surveillance and reporting in intensive care units. J Infect Dis. 2007;195:330-338.
15. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53-59.
16. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592-598.
17. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24:362-386.
18. Lucet JC, Grenet K, Armand-Lefevre L, et al. High prevalence of carriage of methicillin-resistant Staphylococcus aureus at hospital admission in elderly patients: implications for infection control strategies. Infect Control Hosp Epidemiol. 2005;26:121-126.
19. Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Am J Infect Control. 2007;35:73-85.
20. Association for Professionals in Infection Control and Epidemiology. MRSA Laws & Pending Legislation-2009. 2009. Available at: http://www.apic.org/ am/images/maps/mrsa-map.gif. Last accessed March 31, 2010.
21. Harbarth S, Masuet-Aumatell C, Schrenzel J, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interven- tional cohort study. Crit Care. 2006;10:R25.
22. van Trijp MJ, Melles DC, Hendriks WD, et al. Successful control of widespread methicillin-resistant Staphylococcus aureus colonization and infection in a large teaching hospital in the Netherlands. Infect Control Hosp Epidemiol. 2007;28:970-975.
23. Wendt C, Schinke S, Wurttemberger M, et al. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol. 2007;28:1036-1043.
24. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillinresistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44: 178-185.
25. Ridenour G, Lampen R, Federspiel J, et al. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillinresistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol. 2007;28: 1155-1161.
26. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med. 2009;37:1858-1865.
27. Girou E, Pujade G, Legrand P, et al. Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in highrisk hospital areas with a high level of endemic MRSA. Clin Infect Dis. 1998;27:543-550.
28. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, et al. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp Epidemiol. 2006;27:185-187.
29. Saint S, Higgins LA, Nallamothu BK, et al. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control. 2003;31:354-356.
30. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA. 2003;290:1899-1905.
31. Kirkland KB, Weinstein JM. Adverse effects of contact isolation. Lancet. 1999;354:1177-1178.
32. Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc. 1993;88:9-25.
33. Murray DM. Design and Analysis of Group-Randomized Trials. New York, New York: Oxford University Press, Inc.; 1998.
34. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London: Arnold; 2000.
35. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA. 2008;299:1149-1157.
36. Weber DJ, Sickbert-Bennett EE, Brown V, et al. Comparison of hospitalwide surveillance and targeted intensive care unit surveillance of healthcare-associated infections. Infect Control Hosp Epidemiol. 2007; 28:1361-1366.
37. Gulliford MC, Adams G, Ukoumunne OC, et al. Intraclass correlation coefficient and outcome prevalence are associated in clustered binary data. J Clin Epidemiol. 2005;58:246-251.
38. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. Am J Epidemiol. 1999;149:876-883.
39. Centers for Disease Control. Prevention Epicenter Program. 2009. Available at: http://www.cdc.gov/ncidod/dhqp/epicenter.html. Last accessed March 31, 2010.
40. HHS Office for Human Research Protections. OHRP Quality Improvement Activities Frequently Asked Questions. 2009. Available at: http://www.hhs.gov/ ohrp/qualityfaq.html#skipnav. Last accessed March 31, 2010.
41. Brufsky JW, Ross-Degnan D, Calabrese D, et al. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization. Med Care. 1998;36:321-332.
42. Mazor KM, Sabin JE, Boudreau D, et al. Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans. Med Care. 2007;45:S29-S37.
43. Mazor KM, Sabin JE, Goff SL, et al. Cluster randomized trials to study the comparative effectiveness of therapeutics: stakeholders' concerns and recommendations. Pharmacoepidemiol Drug Saf. 2009;18:554-561.
44. Sabin JE, Mazor K, Meterko V, et al. Comparing drug effectiveness at health plans: the ethics of cluster randomized trials. Hastings Cent Rep. 2008;38:39-48.